Agoracom Blog Home

Archive for the ‘Medical Marijuana Stocks’ Category

BMO $BMO.ca marks first foray by a major Canadian bank in #marijuana sector with $175M deal $TBP.ca $N.ca $MCOA $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 2:42 PM on Thursday, January 18th, 2018

  • Bank of Montreal broke new ground Wednesday for the “Big Five” Canadian lenders with its participation in a major marijuana deal
  • Canopy Growth Corp., Canada’s largest licensed producer of medical cannabis, announced an approximately $175-million bought-deal offering Wednesday

Smiths Falls, Ont.-based Canopy Growth Corp., Canada’s largest licensed producer of medical cannabis, announced an approximately $175-million bought-deal offering Wednesday of a little more than five million shares of the company.

Canopy noted in a release that GMP Securities LP and Bank of Montreal-owned BMO Capital Markets were leading the transaction for the company as joint bookrunners, marking the first time a major Canadian bank has helped head an equity financing for a publicly traded company in the medical marijuana industry.

“This is the first time a major Canadian bank-owned brokerage has participated in a cannabis securities issue,” wrote Chris Damas, editor of the BCMI Cannabis Report.

A spokesperson for Canopy confirmed that the transaction marked the first such foray by a Big Five Canadian bank.

“Although this does not guarantee participation in the cannabis sector by all six of the largest Canadian Schedule 1 banks (BMO had already been a banker for cannabis companies), it is very positive for the sector, all things being equal,” Damas added.

Other major Canadian banks have yet to dive into the country’s growing cannabis sector in the same way BMO has, and are likely hesitant to do so given their significant business in the United States, where marijuana is still illegal under federal law. But some banks, including BMO, have provided business accounts for cannabis companies, according to Bloomberg.

That stance may now be starting to soften amid a fundraising spree in the Canadian marijuana industry, which had been taking place without the country’s biggest banks. Companies involved in the already legal medical pot business have been seeking funding to serve the coming recreational market set to be legalized by the federal government this summer.

Royal Bank of Canada told the Financial Post in a statement last week that it “currently does not provide banking services to companies engaged in the production and distribution of marijuana.”

“We recognize that the legislative landscape is evolving and we are undergoing a review of our policies,” added the lender.

A spokesperson for Bank of Nova Scotia told the Post on Friday that “we must balance that with our commitment to effectively manage all business risks.”

“While we understand there is a robust debate in Canada and abroad, our priority is to manage risk for our customers and stakeholders to ensure they are protected,” said Scotiabank’s Rick Roth in an email. “Should there be significant change to industry legislation or regulation, we will revisit our risk assessment and make risk policy adjustments if warranted.”

Toronto-Dominion Bank and the Canadian Imperial Bank of Commerce either declined to comment or had yet to respond as of Thursday morning.

Canopy said its agreement with the underwriters includes an over-allotment option for them, allowing for the purchase of up to 759,000 additional shares at the offering price of $34.60 per share, worth nearly $26.3 million. The company said that the deal is expected to close on Feb. 7, subject to some conditions, and that the net proceeds will be used “for capital expenditures for capacity expansion, working capital, and general corporate requirements.”

Source: http://business.financialpost.com/investing/bank-of-montreal-marks-first-for-major-canadian-lenders-with-175m-marijuana-deal

Namaste $N.ca Announces 5% Equity Purchase LOI with Cannbit Ltd. $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:09 AM on Thursday, January 18th, 2018

Nlogo

  • Company has signed a non-binding Letter of Intent with Israeli medical cannabis producer, Cannbit Ltd
  • Namaste would acquire an equity position of 5% in Cannbit through an investment to be made in a proportion to be determined and agreed by both parties

VANCOUVER, British Columbia, Jan. 18, 2018 – Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N), (FRANKFURT:M5BQ), (OTCMKTS:NXTTF) is pleased to announce that the Company has signed a non-binding Letter of Intent (“LOI”) with Israeli medical cannabis producer, Cannbit Ltd (“Cannbit)” whereby the companies propose to enter into a share purchase agreement and/or a subscription agreement (the “Agreement”) whereby Namaste would acquire an equity position of 5% in Cannbit through an investment to be made in a proportion to be determined and agreed by both parties. Cannbit will also offer Namaste a first right of refusal to purchase an additional 5% equity in shares at the same valuation.

Further to the Company’s September 15th, 2017 announcement of signing a Wholesale Supply Agreement (“Supply Agreement”) with Cannbit, Namaste intends to purchase high-quality medical grade cannabis from Cannbit through the Company’s wholly owned subsidiary, Cannmart Inc. (“Cannmart”). The Company is pleased to have the opportunity to participate in an equity position with Cannbit and in developing a long-term relationship that will be mutually beneficial to both parties. Cannmart is a late stage applicant for an Access to Cannabis for Medical Purposes Regulations (“ACMPR”) medical cannabis “sale-only” license. Through Cannmart, Namaste plans to offer the largest variety of medical cannabis products to its patients through the sourcing of both domestic and internationally imported products. Namaste hopes to leverage its vast expertise with e-commerce, conversion rate optimization and enterprise technology to create Canada’s leading online marketplace for medical cannabis.

Terms of the LOI:

  • Namaste will make an investment in Cannbit in exchange for 5% equity, whereby the amount will be determined by a valuation agreed to by both parties.
  • Namaste will have a first right of refusal to purchase an additional 5% equity position in Cannbit, at the same valuation as originally agreed upon, for a period of one year from the date of execution of the proposed agreement.
  • Closing of the proposed agreement will be contingent upon negotiating and execution of definitive documentation and approval of the terms of the agreement by each party’s respective board of directors and shareholders, if applicable, and by the Canadian Securities Exchange, if applicable.

Namaste’s strategic investment in Cannbit, as well as other domestic and international licensed producers of medical cannabis, will bring value to the company in securing strong partnerships with leading cannabis cultivators to ensure ample supply of the largest variety of high-quality medical cannabis in the Canadian market. Namaste plans to seek additional opportunities by implementing Cannmart’s business model in other regions where the Company maintains significant market share.

Sean Dollinger, President and CEO of Namaste comments: “We’re very much looking forward to working with Cannbit and their team to import exceptionally high-quality medical cannabis into the Canadian market. Namaste expects to see strong value in this investment, as well as through the supply arrangement with Cannbit. We will continue to seek relationships with leading cultivators domestically and abroad. We are highly focused on creating a superior user experience and better availability of products for our patients, and believe this transaction will help us achieve that goal. Thank you to Cannbit’s management team for working hard to secure this LOI and Supply Agreement. We look forward to many years of business together and are excited at the opportunity to give Canadians access to the Israeli cannabis market.”

Yaron Razon, President and CEO of Cannbit Comments “We are very excited to have this partnership and strategic cooperation with Namaste. We believe Namaste is well-positioned with an impressive global marketing and distribution platform and led by a brilliant management team. Together with Namaste, Cannbit will reach many patients across the world with premium medical grade cannabis to help treat their health conditions. We anticipate exploring new opportunities with Namaste and are looking forward to working together soon.”

About Cannbit Ltd.

Cannbit is focused on growing high-quality medical-grade cannabis with advanced technology and agriculture platform while utilizing the best human resources to produce the highest level of quality available that will effectively treat a wide range of illnesses. The Israeli government is expected to approve the export of medical cannabis and Cannbit intends to become Israel’s leading exporter for medical cannabis to legal jurisdictions around the globe. Cannbit’s facility is 4,000 square meters with an additional 10,000 square meters available for expansion and is located in Neot Hakikar, an area well known in the Israeli agricultural community with clear advantages in the cold seasons. Our cultivation is carried out in a sophisticated greenhouse that provides ideal conditions for a variety of cannabis strains. Cannbit’s management is comprised of a group of industry professionals in relevant disciplines.

About Namaste Technologies Inc.

Namaste is the largest online retailer for medical cannabis delivery systems globally. Namaste distributes vaporizers and smoking accessories through e-commerce sites in 26 countries and with 5 distribution hubs located around the world. Namaste has majority market share in Europe and Australia, with operations in the UK, Canada and Germany and has opened new supply channels into emerging markets including Brazil, Mexico and Chile. Namaste, through its acquisition of Cannmart Inc., a Canadian based late-stage applicant for a medical cannabis distribution license (under the ACMPR Program) is pursuing a new revenue vertical in online retail of medical cannabis in the Canadian market. Namaste intends to leverage its existing database of Canadian medical cannabis consumers, along with its expertise in e-commerce to create an online marketplace for medical cannabis patients, offering a larger variety of product and a better user experience.

Forward Looking Information
This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law.

Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com.

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The CSE has neither reviewed nor approved the contents of this press release.

On behalf of the Board of Directors

“Sean Dollinger”
Chief Executive Officer
Direct: +1 (786) 389 9771
Email: info@namastetechnologies.com

Further information on Namaste and its products can be accessed through the links below:

www.namastetechnologies.com
www.namastevaporizers.co.uk
www.everyonedoesit.co.uk
www.australianvaporizers.com.au

Namaste $N.ca $NXTTF Reaffirms Position on No US Exposure and Provides Corporate Response to Recision of Cole Memo and CSA Statement $ATT.ca $ABCN.ca $ACG.ca $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 8:36 AM on Wednesday, January 17th, 2018

Nlogo

  • Reaffirms its commitment to operations exclusively within medical or recreational cannabis legal jurisdictions
  • Company would like to express very clearly that it does not hold any US assets nor does it intend on participating in any US operations or investments

VANCOUVER, British Columbia, Jan. 17, 2018 – Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N), (FRANKFURT:M5BQ), (OTCMKTS:NXTTF) would like to reaffirm its commitment to operations exclusively within medical or recreational cannabis legal jurisdictions. Further to the Company’s Nov 28, 2017 press release, and in lieu of the recent rescission of the Cole Memorandum by US Attorney General Jeff Sessions, Namaste’s position on staying out of the US cannabis market remains firm. The Company would like to express very clearly that it does not hold any US assets nor does it intend on participating in any US operations or investments. Namaste is highly focused on the expansion of its Canadian operations through the launch of its online medical cannabis marketplace. Management will have no involvement in operations or investments in any illegal jurisdictions which present any risk to the Company and/or its shareholders.

On January 12, 2018, the Canadian Securities Administrators (“CSA”) issued a statement following the rescission, whereby the CSA gave notice that it would re-examine its disclosure-based policy in relation to Canadian cannabis companies with any US operations or investments. Namaste believes that the CSA’s statement is in-line with the Company’s position and short-term outlook on the cannabis market in the United States.

Namaste will continue to focus on expansion of its international operations in progressive, legal markets by leveraging its technology and existing databases of cannabis consumers in countries around the world. Namaste, through its wholly owned subsidiary, Cannmart Inc. (“Cannmart”) is developing an online marketplace for medical cannabis that will offer patients the largest variety of product sourced from domestic and international producers. The launch of Cannmart is significant to Namaste, as the Company intends to follow the same strategy in other legal markets where it has established a strong presence.

Management Commentary
Sean Dollinger, President and CEO of Namaste comments: “We’re very pleased to have divested our US assets and operations. Namaste will continue focusing its efforts on progressive, legal markets like Canada and emerging legal cannabis markets like Australia and will remain uninvolved with any US cannabis operations until there are major changes to US federal laws.”

About Namaste Technologies Inc.
Namaste is the largest online retailer for medical cannabis delivery systems globally. Namaste distributes vaporizers and smoking accessories through e-commerce sites in 26 countries and with 5 distribution hubs located around the world. Namaste has majority market share in Europe and Australia, with operations in the UK, US, Canada and Germany and has opened new supply channels into emerging markets including Brazil, Mexico and Chile. Namaste, through its acquisition of Cannmart Inc., a Canadian based late-stage applicant for a medical cannabis distribution license (under the ACMPR Program) is pursuing a new revenue vertical in online retail of medical cannabis in the Canadian market. Namaste intends to leverage its existing database of Canadian medical cannabis consumers, along with its expertise in e-commerce to create an online marketplace for medical cannabis patients, offering a larger variety of product and a better user experience.

Forward Looking Information
This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law.

Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com.

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The CSE has neither reviewed nor approved the contents of this press release.

On behalf of the Board of Directors

“Sean Dollinger”
Chief Executive Officer
Direct: +1 (786) 389 9771
Email: info@namastetechnologies.com

Further information on the Company and its products can be accessed through the links below:

www.namastetechnologies.com
www.namastevaporizers.co.uk
www.everyonedoesit.co.uk
www.australianvaporizers.com.au

Namaste $N.ca $NXTTF Announces Participation as Lead Order in Atlas Growers Private Placement and Secures 20% of Net Production $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:17 AM on Tuesday, January 16th, 2018

Nlogo

  • Participating as a lead order in a private placement offering by Atlas Growers Ltd.
  • In consideration of the investment, Atlas and Namaste’s wholly owned subsidiary, Cannmart Inc. have entered in to a Supply Agreement
  • Atlas agreed to guarantee supply to Cannmart by offering first right of refusal for a minimum of 20% of the net production of medical cannabis through Atlas

VANCOUVER, British Columbia, Jan. 16, 2018 – Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N), (FRANKFURT:M5BQ), (OTCMKTS:NXTTF) is pleased to announce that the Company is participating as a lead order in a private placement offering (“Private Placement”) by Atlas Growers Ltd. (“Atlas”), which is a late-stage applicant for an Access to Cannabis for Medical Purposes (“ACMPR”) cultivation and sales license. In consideration of the investment, Atlas and Namaste’s wholly owned subsidiary, Cannmart Inc. (“Cannmart”) have entered in to a Supply Agreement (the “Supply Agreement”) whereby Atlas agrees to guarantee supply to Cannmart by offering first right of refusal for a minimum of 20% of the net production of medical cannabis through Atlas.

The Company’s participation in the Private Placement and subsequent Supply Agreement offer significant value to Namaste shareholders not only as an investment, but also in securing a reliable supply of high quality medical cannabis. The Company believes Atlas’ strong management team and business plan provide a strategic partnership opportunity with Atlas to ensure a guaranteed cannabis supply to Namaste, while at the same time broadening Atlas’ exposure to the market via Cannmart’s online retail channels. Namaste has completed the Subscription Agreement under the terms of the Private Placement, for C $200,000 in exchange for 200,000 Class B Common shares of Atlas stock at a price of C $1.00 per common share. The Supply Agreement will allow Cannmart to purchase bulk quantities of medical cannabis from Atlas based on the terms below.

Supply Agreement Terms

  • Atlas commits to Cannmart a first right of refusal to purchase up to 20% of Atlas’ production
  • The term of the Supply Agreement is 24 months
  • Purchase orders are to be submitted at least 14 days in advance of requested delivery date
  • Payment terms are 30 days from delivery of a purchase order
  • Cannmart will be responsible for delivery charges
  • The Supply Agreement is subject to both companies receiving their ACMPR licenses.

Namaste will continue to explore additional opportunities for investments in domestic and international medical cannabis producers as it sees great value in securing equity and building a strong and reliable supply chain for Cannmart’s patients. Namaste plans to leverage its vast e-commerce expertise and technology, along with its existing consumer databases and site traffic, to create the largest online marketplace for medical cannabis in Canada. This strategic investment in Atlas clearly defines the Company’s strategy in developing strong supply relationships to achieve its goals. The Canadian market offers some unique opportunities as it relates to craft and/or boutique producers, and Namaste believes this niche will add significant value to its platform.   Canada has a long history of producing some of the highest quality and most sought-after cannabis in the world, and it is Namaste’s intention to ensure all producers have access to its distribution channels. Namaste expects to see a growing demand for the cannabis produced in these markets, much like that seen in the craft beer and wine industry. This partnership demonstrates the Company’s intention to leverage a broad range of supply chains, in an attempt to meet the wants and needs of our patients.

Management Commentary
Sean Dollinger, President and CEO of Namaste comments: “We’re very excited to be participating in this opportunity with Atlas and their team. We believe that Atlas will be an amazing strategic partner for Namaste in its ability to guarantee a reliable supply of cannabis for Cannmart. We are looking forward to working with Atlas to provide value and exposure for their brand. Namaste will continue to seek opportunities for partnerships with large and small ACMPR producers and will also focus on growing our vendor database to include premium craft cannabis brands. The opportunity to participate in this private placement brings value to the company as an investment but also in implementation of our strategy to become the most diversified marketplace for medical cannabis.”

Sheldon Croome, President and CEO of Atlas comments: “Our team is pleased to work with Namaste by providing our array of high quality cannabis products to their customers. In partnering with Namaste, both companies gain a significant strategic advantage as the market moves towards recreational legalization in 2018, and as the medical cannabis market expands. Namaste will be instrumental in bringing Atlas’ products to Eastern Canadian customers with the fastest possible delivery times, which we feel to be of excellent value to the end consumer. We are excited to bring additional value to Namaste and look forward to a strong, long term partnership.”

About Namaste Technologies Inc. 
Namaste is the largest online retailer for medical cannabis delivery systems globally. Namaste distributes vaporizers and smoking accessories through e-commerce sites in 26 countries and with 5 distribution hubs located around the world. Namaste has majority market share in Europe and Australia, with operations in the UK, US, Canada and Germany and has opened new supply channels into emerging markets including Brazil, Mexico and Chile. Namaste, through its acquisition of Cannmart Inc., a Canadian based late-stage applicant for a medical cannabis distribution license (under the ACMPR Program) is pursuing a new revenue vertical in online retail of medical cannabis in the Canadian market. Namaste intends to leverage its existing database of Canadian medical cannabis consumers, along with its expertise in e-commerce to create an online marketplace for medical cannabis patients, offering a larger variety of product and a better user experience.

Forward Looking Information

This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law.

Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com.

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The CSE has neither reviewed nor approved the contents of this press release.

On behalf of the Board of Directors

“Sean Dollinger”
Chief Executive Officer
Direct: +1 (786) 389 9771
Email: info@namastetechnologies.com

Further information on Namaste and its products can be accessed through the links below:

www.namastetechnologies.com
www.namastevaporizers.co.uk
www.everyonedoesit.co.uk
www.australianvaporizers.com.au

Further information on Atlas can be accessed through the link below:

www.atlasgrowers.com

Tetra Bio-Pharma $TBP.ca Receives Approval from Health Canada of its Phase 1 Clinical Trial with PPP005 (Cannabis Oil) $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:13 AM on Tuesday, January 16th, 2018

Logo tetrabiopharma rgb web

  • Received a No Objection Letter (NOL) from the Therapeutic Products Directorate (TPD),
  • Health Canada to evaluate the safety, pharmacokinetics and pharmacodynamics of its cannabis oil PPP005

OTTAWA, ONTARIO–(Jan. 16, 2018) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce that it has received a No Objection Letter (NOL) from the Therapeutic Products Directorate (TPD), Health Canada to evaluate the safety, pharmacokinetics and pharmacodynamics of its cannabis oil PPP005.

According to Health Canada data1, the annual Canadian cannabis oil production for medical purposes was 22,766 kg between October 1st 2016 and September 30th 2017, and is growing continuously. In the third quarter of 2017, it grew 24% from Q2 (Apr-Jun) to Q3 (Jul-Sep)1. According to an Eight Capital analysis2, the cannabis oil market is expected to reach 1.5B$ in 2024.

The launch of this trial is the first step in Tetra’s plans to commercialize natural health products with its partners. The corporation will develop cannabis-based supplements for commercialization under the Natural Health Product regulations in Canada and in other countries where regulatory authorities have a recognized pathway for approval and commercialization of such products. The trial will eventually include formulations that will be registered as drugs under Health Canada’s TPD regulatory pathway. “Tetra Bio-Pharma Inc. seeks to become an important player in the retail market post legalization and this clinical trial is part of the sales and marketing strategy required to effectively penetrate the lucrative pharmacy and health stores retail markets,” states Bernard Fortier, CEO of Tetra.

Tetra’s vision is to develop an evidence-based approach, thereby allowing pharmacists to dispense these medicines to patients in need. Despite the growing popularity of cannabis oils, physicians and pharmacists across Canada are still hesitant to support the use of these products because of the lack of data supporting its medical use. Dr. Guy Chamberland, Chief Science Officer, commented: “This trial is part of Tetra’s corporate strategy to develop the science required to commercialize safe and efficacious cannabis oil products post-legalization and to create innovative oral drug formulations for the development of medicines in the management of pain, anxiety and the treatment of cancer.”

In that respect, Tetra’s scientific team is supporting the strategy by initiating a phase 1 clinical trial to characterize the safe use of these cannabis oil medicines in humans. Tetra has worked with Altasciences Clinical Research for the preparation of the Clinical Trial Application (CTA) for the conduct of a double-blind phase 1 study to assess safety, tolerability and pharmacokinetics of single and multiple daily doses of cannabis (Delta-9-tetrahydrocannabinol/Cannabidiol) oil capsules administered to healthy human volunteers. Health Canada issued a No Objection Letter for the conduct of the phase I clinical trial on January 12nd, 2018. Altasciences Clinical Research will be initiating the clinical trial activities in the coming weeks. The cannabis oil is manufactured by Tetra’s partner, Aphria Inc.

1: Health Canada Market Data, [https://www.canada.ca/en/health-canada/services/drugs-health-products/medical-use-marijuana/licensed-producers/market-data.html] 2: Cannabis Sector, Eight Capital Estimates, July 2017About Tetra Bio-Pharma:

Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.

More information at: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a license for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
(514) 360-8040 Ext. 210
anne-sophie.courtois@tetrabiopharma.com

Marijuana Company of America $MCOA Launches New CBD Product hempSMART™ Pain Cream $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:37 AM on Thursday, January 11th, 2018

15233 mcoa

  • Announced the launch of hempSMART Pain Cream
  • Each bottle of hempSMART Pain Cream is formulated with 300mg of full spectrum non-psychoactive Cannabidiol (CBD) derived from industrial hemp
  • Topical wellness product is formulated to help reduce minor discomfort, support normal joint mobility, and promote muscle relaxation on areas that it is applied
  • MCOA CEO Donald Steinberg commented, “We are excited to announce the expansion of our hempSMART personal care product line to include pain management products. We will continue to expand our health and wellness lines in 2018 to include more products...”

ESCONDIDO, Calif., Jan. 11, 2018 – – MARIJUANA COMPANY OF AMERICA INC. (“MCOA” or the “Company”) (OTC:MCOA), an innovative hemp and cannabis corporation, through its wholly owned subsidiary hempSMART™, Inc., is pleased to announce the launch of hempSMART Pain Cream.

Each bottle of hempSMART Pain Cream is formulated with 300mg of full spectrum non-psychoactive Cannabidiol (CBD) derived from industrial hemp. The newly developed product contains a synergistic combination of natural botanicals and full spectrum hemp extract featuring CBD, CBG and a broad range of terpenes. The Company’s proprietary blend of Ayurvedic herbs along with Menthol, Cayenne Pepper Extract, Rosemary Oil, Aloe Gel, White Willow Bark, Arnica, Wintergreen Extract and Tea Tree Oil, provides an immediate cooling and soothing sensation. This topical wellness product is formulated to help reduce minor discomfort, support normal joint mobility, and promote muscle relaxation on areas that it is applied.

MCOA CEO Donald Steinberg commented, “We are excited to announce the expansion of our hempSMART personal care product line to include pain management products. We will continue to expand our health and wellness lines in 2018 to include more products. We expect that our Pain Cream will be enthusiastically received by our affiliates and customers.

About Marijuana Company of America, Inc.
MCOA is a corporation which participates in: (1) product research and development of legal hemp-based consumer products under the brand name “hempSMART™”, that targets general health and well-being; (2) an affiliate marketing program to promote and sell its legal hemp-based consumer products containing CBD; (3) leasing of real property to separate business entities engaged in the growth and sale of cannabis in those states and jurisdictions where cannabis has been legalized and properly regulated for medicinal and recreations use; and, (4) the expansion of its business into ancillary areas of the legalized cannabis and hemp industry, as the legalized markets and opportunities in this segment mature and develop.

About Our hempSMART Products Containing CBD
The United States Food and Drug Administration (FDA) has not recognized CBD as a safe and effective drug for any indication. Our products containing CBD derived from industrial hemp are not marketed or sold based upon claims that their use is safe and effective treatment for any medical condition as drugs or dietary supplements subject to the FDA’s jurisdiction.

Forward Looking Statements
This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-12G, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

For more information, please visit the Company’s websites at:

MarijuanaCompanyofAmerica.com
hempSMART.com
NetworkNewsWire/MCOA

Marijuana Company of America, Inc.
Investor Relations
1+(888)-777-4362
IR@mcoa.club

Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Namaste $N.ca $NXTTF and Phivida $VIDA.ca Announce Exclusive Supply Agreement $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:18 AM on Thursday, January 11th, 2018

Nlogo

  • Announce that it has signed a Global Digital Reseller-Supply Agreement with Phivida Holdings Inc.
  • Namaste has been approved as the preferred global online retailer and digital affiliate marketing partner for Phivida’s product line of premium hemp-derived Cannabidiol infused functional beverages and clinical health products

VANCOUVER, British Columbia, Jan. 11, 2018 — Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N), (FRANKFURT:M5BQ), (OTCMKTS:NXTTF) is pleased to announce that it has signed a Global Digital Reseller-Supply Agreement (the “Agreement”) with Phivida Holdings Inc. (“Phivida”) (CSE:VIDA), (OTCMKTS:PHVAF).

As key terms in the agreement, Namaste has been approved as the preferred global online retailer and digital affiliate marketing partner for Phivida’s product line of premium hemp-derived Cannabidiol (“CBD”) infused functional beverages and clinical health products. The agreement includes a global online territory, targeting the launch in Germany and Australia (the “Territories”).

Phivida CBD beverages, extracts, juices and shots are professionally formulated by health care practitioners, made with premium ingredients, tested for quality, safety and manufactured to GMP standards. This Agreement represents a strategic initiative between both companies to promote high quality CBD products through Namaste’s platform and to the Company’s existing databases of users within the Territories. CBD is a cannabinoid compound which can be derived from both cannabis and hemp plants and plays a vital role in the emerging global medical cannabis market.

With Phivida’s management team having a strong background from the beverage industry and branding, including former senior executives from Redbull, Proctor and Gamble and McKesson’s, Namaste is pleased to be able to offer Phivida’s premium CBD beverages and infusions to its patients and practitioners globally, with an initial launch in Australia and Germany.

Terms of the Agreement

  • Namaste has exclusive rights for online retail of Phivida’s products in the Territories
  • The Agreement is valid for a 24-month period
  • The Agreement payment terms are net 30 days
  • Namaste shall be responsible for delivery costs
  • Namaste will under no circumstance retail PHIVIDA products for a price that is less than the regular retail price at which the products are advertised on PHIVIDA’s website
  • The Agreement states that all online product marketing expenses within the Territories will be shared equally between PHIVIDA and Namaste
  • The Agreement is subject to obtaining a legal opinion from a designated legal firm, agreed to by both parties

Namaste’s globally diversified network of e-commerce sites and distribution centers will allow Namaste, in its partnership with Phivida, to reach users in new and emerging medical cannabinoid based medical and consumer health markets. This Agreement further represents Namaste’s commitment to deploy its strategic initiatives in an effort to bring the most innovative products to market. Namaste’s growing global database of consumers continues to provide value to the Company and its partners, as it aims to leverage its technical expertise relating to its cutting-edge SEO and machine learning technologies.

This Agreement represents a pilot project between both companies whereby Namaste will distribute Phivida’s proprietary CBD beverages and infused products within the designated territories. Both companies intend on further expanding distribution through other markets where Namaste maintains significant market share.

While the Canadian market remains a primary focus for Namaste, it has identified additional opportunities in the Australian and German markets, as both countries continue to demonstrate a keen willingness to move closer towards full legalization. This partnership will allow Namaste to transition seamlessly into both markets, as it looks to broaden the scope of the products and services it provides. This Agreement represents an important step for Namaste as it looks to expand its presence into emerging markets and believes Phivida’s CBD beverages, oils and infusions offer Namaste an incredible opportunity to expand its offering globally.

Management Commentary

Sean Dollinger, President and CEO of Namaste comments: “Namaste is extremely excited to be partnering with Phivida and its world-class management team. We’re looking forward to entering the beverage space together with Phivida as we believe there is significant demand for these products in our market. Many of our successes to this point can be largely attributed to our keen ability in identifying industry leaders and then forming strategic alliances.  Our partnership with Phivida further demonstrates that ability, and we feel very optimistic to be collaborating with a management team whose pedigree speaks for itself.   We would like to thank Phivida for granting Namaste rights of its online retail products in the Territories, as we expand our presence globally.

We fully expect this partnership to evolve and fully intend on exhausting all opportunities whereby both parties are able grow and expand their respective market share. Not only does this offer Namaste the ability to expand its product line but so too does it help us in penetrating new markets as we look to create the world’s most expansive online medical cannabis marketplace.”

John – David Belfontaine, President and CEO of Phivida reports: “As Phivida continues to expand is CBD product offerings into a $1 Trillion global health and wellness marketi, it is critical that we secure the strongest distribution partners. Ecommerce and digital marketing is a core horizontal within our greater strategic business plan, and Namaste is an ideal partner to expand our online presence into emerging markets around the world. We look forward to launching our global digital marketing and distribution platform with Namaste’s support as a key strategic partner.”

About Namaste Technologies Inc. 
Namaste is the largest online retailer for medical cannabis delivery systems globally. Namaste distributes vaporizers and smoking accessories through e-commerce sites in 26 countries and with 5 distribution hubs located around the world. Namaste has majority market share in Europe and Australia, with operations in the UK, US, Canada and Germany and has opened new supply channels into emerging markets including Brazil, Mexico and Chile. Namaste, through its acquisition of Cannmart Inc., a Canadian based late-stage applicant for a medical cannabis distribution license (under the ACMPR Program) is pursuing a new revenue vertical in online retail of medical cannabis in the Canadian market. Namaste intends to leverage its existing database of Canadian medical cannabis consumers, along with its expertise in e-commerce to create an online marketplace for medical cannabis patients, offering a larger variety of product and a better user experience.

About Phivida 
Phivida [“fiii-vee-daa”] is a publicly traded company listed on the Canadian Securities Exchange under the ticker symbol “VIDA”. Phivida is a premiere brand of cannabidiol (“CBD”) infused functional foods, beverages and clinical health products, poised for global distribution. Using nanoencapsulation technology, Phivida converts lipid based cannabinoids into water soluble delivery format, enhancing bioavailability, and timed released within the body. Phivida’s nanoencapsulated CBD is infused into CBD beverages, foods and supplements containing a proprietary blend of phytonutraceuticals studied to target a range of health conditions, from chronic pain to terminal diseases. Phivida Enhanced Inc. (a wholly owned subsidiary of Phivida Holdings Inc.) is the clinical division of Phivida responsible for the formulation, manufacturing and distribution of the professional line clinical products under the brand name Vida+. These clinical grade CBD products include sublingual’s, hard capsules and other full spectrum CBD-hemp oil extract infused nutraceuticals and natural health products. The Vida+ label is a professional line of products clinical grade for higher potency and are third party laboratory tested for cannabinoid potency, terpenes, residual solvents, bacteria and pesticides.  Celebrating; Health and Wellness, In Harmony™, Phivida’s mission is to lead the alternative health care sector as the benchmark quality standard in premium cannabinoid infused foods, beverages and clinical products, with a dedication to research, education and investing back into the communities that we so proudly serve.

For investor relations inquiries and updates, please contact Phivida via the information listed below.

Website www.phivida.com  Toll free +1 (844) 744-6646 (ext. #2)  E-mail IR@phivida.com     Twitter  https://twitter.com/Phivida Facebook                                  https://www.facebook.com/phivida YouTube  https://www.youtube.com/watch?v=YqvHSMbhKwQ&t=7s

Forward Looking Information

This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law.

Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com.

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The CSE has neither reviewed nor approved the contents of this press release.

On behalf of the Board of Directors

“Sean Dollinger”
Chief Executive Officer
Direct: +1 (786) 389 9771
Email: info@namastetechnologies.com

Further information on the Company and its products can be accessed through the links below:

www.namastetechnologies.com
www.namastevaporizers.co.uk
www.everyonedoesit.co.uk

https://blog.euromonitor.com/2012/11/health-and-wellness-the-trillion-dollar-industry-in-2017-key-research-highlights.html

Namaste $N.ca Announces Services Agreement With #Cannamerx Cannabis Mercantile Exchange $ATT.ca $ABCN.ca $ACG.ca $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 8:23 AM on Tuesday, January 9th, 2018

Nlogo

  • Announced that it has entered into a Services Agreement with Cannamerx;
  • Canada’s first online marketplace for the wholesale purchase of medical cannabis certified under the Access to Cannabis for Medical Purposes Regulations
  • All bids submitted over the platform are binding;
  • Sale transactions are Ex Works;
  • Cannamerx offers strong buyer protection to ensure products match descriptions;

VANCOUVER, BRITISH COLUMBIA, Jan. 09, 2018 – Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE: N)(FRANKFURT: M5BQ)(OTCMKTS: NXTTF) is pleased to announce that it has entered into a Services Agreement (the “Agreement”) with 3955 Trading Inc. (“Cannamerx”), Canada’s first online marketplace for the wholesale purchase of medical cannabis certified under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”). Cannamerx is a fully automated, ACMPR-compliant forward auction trading platform for bulk cannabis and cannabis products in Canada. Developed in close collaboration with Canadian licensed producers, Cannamerx is designed to facilitate the trade of bulk cannabis and cannabis products between licensed producers throughout the country. Namaste believes that Cannamerx’s platform will offer strategic benefits to the Company’s wholly owned subsidiary, Cannmart Inc. (“Cannmart”), which is a late stage ACMPR applicant for a medical cannabis “sale-only” license. Through Cannmart, Namaste will create an online retail marketplace for medical cannabis that will offer the largest variety of products sourced from ACMPR licensed producers as well as international cultivators.

Terms of the Agreement:

  • All bids submitted over the platform are binding;
  • Sale transactions are Ex Works;
  • Cannamerx offers strong buyer protection to ensure products match descriptions;
  • Cannamerx ensures that all ACMPR compliant;
  • Cannamerx is strictly a business to business marketplace;
  • Cannamerx does not charge sign-up or listing fees;
  • Cannamerx does not charge any buyer commission;
  • Bidding on Cannamerx is anonymous; and
  • The Agreement is non-exclusive to Cannmart.

Using the Cannamerx platform will enhance Namaste’s ability to efficiently source cannabis and cannabis products from small-scale licensed producers throughout Canada, creating a diverse product selection for Cannmart’s online marketplace customers.  While large licensed producers will continue to play a vital role in Namaste’s distribution, the Company believes that the Agreement will allow the Company to connect customers with the craft cannabis market, an important niche market that could experience significant growth similar to the craft beer and wine industries.

In addition to the announcement of the Agreement, Namaste would like to announce that Mr. Clifford Stark will be leaving Namaste’s board of directors in pursuit of a new business venture. Mr. Stark has provided Namaste with valuable advice and insight during his position as an active board member of Namaste’s team. The Company would like to thank Mr. Stark for his service and wishes him best of luck in his future endeavors.

Management Commentary
“We are proud to welcome Namaste to Cannamerx,” said Dietwald Claus, CEO of 3955 Trading Inc., which owns and operates Cannamerx. “We developed Cannamerx to provide Canadian licensed producers with an effective, easy-to-use, ACMPR-compliant platform for the trade of wholesale cannabis and cannabis products in Canada. By bringing together licensed producers, processors, and retailers from across the country on a single trading platform, we anticipate that Cannamerx will play a critical role in growing a diversified and robust Canadian cannabis industry. Namaste’s decision to join Cannamerx is a strong vote of confidence in our technology and business model. We look forward to welcoming more participants over the coming months as Canada prepares to legalize recreational cannabis.”

Sean Dollinger, President and CEO of Namaste comments, “This Agreement represents a unique opportunity for both parties, as we look for new ways to increase the appeal of our online marketplace. Our relationship with Cannamerx is not intended to replace our existing supply channels, but rather to broaden the selection of quality cannabis products that we are able to provide to our customers. Namaste believes Cannamerx fits well with our purchasing strategy moving forward, and we anticipate Cannamerx playing a significant role in helping us access cannabis from smaller licensed producers to supply Canadian consumers with the most diverse selection in a cannabis space.”

“In addition to the benefits Cannamerx provides Namaste, we believe Cannamerx provides a great channel for licensed producers looking to wholesale their cannabis. Namaste is committed to providing Canadian cannabis users with easy access to the widest range of cannabis products and this agreement helps fast track our efforts in achieving those goals.”

About Namaste Technologies Inc. 
Namaste is the largest online retailer for medical cannabis delivery systems globally. Namaste distributes vaporizers and smoking accessories through e-commerce sites in 26 countries and with 5 distribution hubs located around the world. Namaste has majority market share in Europe and Australia, with operations in the UK, US, Canada and Germany and has opened new supply channels into emerging markets including Brazil, Mexico and Chile. Namaste, through its acquisition of Cannmart Inc., a Canadian based late-stage applicant for a medical cannabis distribution license (under the ACMPR Program) is pursuing a new revenue vertical in online retail of medical cannabis in the Canadian market. Namaste intends to leverage its existing database of Canadian medical cannabis consumers, along with its expertise in e-commerce to create an online marketplace for medical cannabis patients, offering a larger variety of product and a better user experience.

On behalf of the Board of Directors

“Sean Dollinger”
Chief Executive Officer
Direct: +1 (786) 389 9771
Email: info@namastetechnologies.com

Further information on the Company and its products can be accessed through the links below:

www.namastetechnologies.com
www.namastevaporizers.co.uk
www.everyonedoesit.co.uk

FORWARD-LOOKING INFORMATION This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995. The CSE has neither reviewed nor approved the contents of this press release.

Canadian #cannabis producers set their sights on global domination $N.ca $TBP.ca $MCOA $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 11:10 AM on Friday, January 5th, 2018

  • Medical research forcing an end to prohibition
  • “I’ve never experienced anything like this,” says Ranjeev Dhillon, a corporate lawyer and partner at the law firm Bennett Jones. Most of his practice now centres on the cannabis export business.
  • In recent months, more than a dozen countries have legalized medical marijuana

Medical marijuana consumers in Prague rang in 2018 with a new Canadian import, Tilray Milled Cannabis, a high THC marijuana product grown on Vancouver Island.

The Czech Republic is just the latest nation to sell Canadian weed, joining Germany, Australia, New Zealand and a growing list of other nations which are turning to Canada as a safe and legal source for medical grade cannabis.

In recent months, more than a dozen countries have legalized medical marijuana. New laws are pending in at least a dozen more as national regulators and even the World Health Organization recognize legitimate medical uses for a drug which had long been banned under international treaties.

The moves have sparked an unprecedented demand for legally grown, high quality marijuana, as well as the oil which is extracted from it. Seven Canadian producers have been granted licences to export the crop. By the end of March they will have sent 528 kilograms of dried cannabis flower and 911 litres of oil overseas. That may well be just an initial trickle, as the floodgates open on an international medical cannabis market.

“I’ve never experienced anything like this,” says Ranjeev Dhillon, a corporate lawyer and partner at the law firm Bennett Jones. Most of his practice now centres on the cannabis export business.

Brendan Kennedy of Tilray says Canada is the source of the safest product when regulators in other countries go looking for medical marijuana. (Evan Mitsui/CBC)

“I think it means that we’ll be a global player,” he says, stressing this is a positive development for the Canadian economy. “This could be our opportunity to be viewed the same as we are in mining or hockey. We’ll be world class and be world leaders and I think that will stay to be the case for a very, very long time.”

Medical research forcing an end to prohibition

For decades an international ban on the production and use of cannabis kept to a minimum any legitimate research into potential medical uses. Prohibition ensured that marijuana cultivation stayed in the hands of illegal growers, and distribution was limited to the criminal underground.

But many users saw value in cannabis as treatment for a variety of conditions, ranging from controlling epileptic seizures to pain relief to stress control.

Israeli scientist Raphael Mechoulam began limited research on the drug in the early 1960s, which led to the discovery of the human endocannabinoid system. By the mid-1990s, scientists determined that cannabinoid receptors play a vital role in the function of the human body. For the first time synthetic cannabinoid derivatives were approved for medical use, primarily for the treatment of nausea and wasting syndrome.

At the same time anecdotal evidence was building to suggest cannabis could have other, more widespread medical uses. Patients who claimed benefits from cannabis went to court seeking the right to use marijuana as medicine without facing the risk of criminal prosecution.

In 2000 the Ontario Court of Appeal ruled that Terry Parker, a man with severe epilepsy, should have the right to use marijuana to moderate his severe seizures.

One year later, Canada’s Medical Marijuana Access Program was introduced, allowing patients who had obtained a doctor’s consent to grow their own marijuana under a special permit. By 2013 more than 28,000 Canadians had been granted personal use production licences, leading to a flood of unregulated home-grow operations, and along with it a risk of fires, mould contamination in homes, and legally grown weed being diverted to the black market.

In an effort to crack down on the home grow-ops, the Harper Conservative government introduced new legislation that established legal grow operations which could provide medical marijuana through a mail order service. The Marijuana for Medical Purposes regulations, enacted in 2014, set Canada apart as the first nation to establish a regulated commercial cannabis cultivation industry.

Canadian pot finds a role in the world market

As Canada moves towards legal recreational weed in July, the number of licensed growers has swelled to 84, production is skyrocketing, and research into new growing techniques and improved strains is increasing exponentially. This has placed Canada in a unique role as other nations scramble to find safe and legal supplies of medical cannabis.

Cam Battley, executive vice president of Aurora, shows off Aurora Vie’s Pointe-Claire, Que., facility. Canadian producers have expertise in greenhouse technology, extraction methods, strains and genetics. (CBC)

“When regulators in other countries are looking for a product, Canada is really the source of the safest product. It’s the safest bet,” explains Brendan Kennedy, the CEO of Nanaimo-based Tilray, a pioneer in cannabis exports.

Tilray is among several Canadian producers already exporting to Germany, which established a widespread marijuana access program last spring. Not only is cannabis stocked in German pharmacies, the government pays for the drug under its government health insurance program.

Until it can establish a domestic industry, Germany is importing from Canada. Along with Tilray, Canadian producers Aurora, Cronos and Canopy Growth are tapping the German market. Aurora has even gone a step further, purchasing pharmaceutical supplier Pedanios, with an eye to expanding its distribution in the European market.

Following Germany, several other European countries, including Greece, Italy, Poland and the Czech Republic, passed new medical cannabis laws. Several others are following. A report published in November places the value of the European cannabis market at $84 billion Cdn a year.

That’s led Tilray to begin construction of a $30-million production facility in Portugal to help supply the growing market.

Beyond exports, Canada has expertise

“Part of the reason we decided to invest in a cultivation facility in Portugal was that we also saw a massive increase in demand for medical cannabis product in the EU,” explains Kennedy, who sees a bright future well beyond Canadian exports.

Canadian expertise in growing and greenhouse technology, extraction methods, strains and genetics, along with plain old business know-how, are also in demand. In addition to exports, Canada’s cannabis companies are also teaming up with local partners to build facilities in Germany, Denmark and Israel.

Australia is seen as another prize for Canadian producers. When it announced last February that it would allow importation, Canadian producers Aurora, CannTrust, Canopy, MedReleaf and Tilray swooped in, not only with bags of weed and vials of oil, but with partnerships to build facilities there.

Peru and Mexico have also passed legislation to legalize medical cannabis, and Canadian companies are promising further announcements soon. Overall, they say, the world market could be worth around $200 billion.

What it all means

The rapid legalization of medical cannabis has spurred new research into potential treatments using the drug. In Israel, where the medical research began, there are about 120 trials underway using components of the marijuana plant.

Neil Closner, CEO of Ontario-based MedReleaf, believes Canadian medical marijuana producers have the potential to become global giants. (Canadian Press)

As cures and treatments are discovered and proven, the role of cannabis is sure to expand, creating even greater potential beyond flowers and oil. CEO of Markham-based MedReleaf Neil Closner believes at least two or three of Canada’s producers will become global giants.

“I think overall who wins is Canada. I think we’ve got a leg up on the rest of the world, which is very exciting at a national level for us. I’d like to think that MedReleaf is strongly positioned to be one of the few handfuls of global winners.”

And while California is the latest U.S. state to legalize marijuana, American producers are shut out of the global market because of the federal prohibition on the drug.

That leaves Canada room to pursue the international market and all the potential riches that go with it.

Source: http://www.cbc.ca/news/business/medical-marijuana-canadian-export-1.4470407

Namaste $N.ca $NXTTF Live 420 Stream: Latest Press Releases | Aurora Cannabis $ACB.ca – Live Today At 4.20pm EST

Posted by AGORACOM-JC at 4:05 PM on Wednesday, January 3rd, 2018